Study Highlight: Eating olive oil more frequently among healthy obese adults was associated with less platelet activity in the blood. Platelets are blood cell fragments that stick together to form clots. Embargoed until 3 p.m. CT/4 p.m. ET, Thursday., March 7, 2019 (NewMediaWire) - March 07, 2019 - HOUSTON - In a group of healthy, but obese adults, eating olive oil at least once a week was associated with less platelet activity in the blood, which may reduce the tendency of blood to clot and block blood flow, according to preliminary research presented at the American Heart Association’s Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2019, a premier global exchange of the latest advances in population-based cardiovascular science for researchers and clinicians. Platelets are blood cell fragments that stick together and form clumps and clots when they are activated. They contribute to the buildup of artery-clogging plaque, known as atherosclerosis, the condition which underlies most heart attacks and strokes, according to lead study author Sean P. Heffron, M.D., M.S., M.Sc., assistant professor at NYU School of Medicine and the NYU Center for the Prevention of Cardiovascular Disease in New York, New York. Using food frequency surveys, researchers determined how often 63 obese, nonsmoking, non-diabetic study participants ate olive oil. The participants’ average age was 32.2 years and their average body mass index (BMI) was 44.1. Obesity is defined as having a body mass index – a measure of body weight – over 30. Researchers found that those who ate olive oil at least once a week had lower platelet activation than participants whose ate it oil less often, and that the lowest levels of platelet aggregation were observed among those who ate olive oil more frequently. “People who are obese are at increased risk of having a heart attack, stroke or other cardiovascular event, even if they don’t have diabetes or other obesity-associated conditions. Our study suggests that choosing to eat olive oil may have the potential to help modify that risk, potentially lowering an obese person’s threat of having a heart attack or stroke,” Heffron said. “To our knowledge, this is the first study to assess the effects of dietary composition, olive oil specifically, on platelet function in obese patients,” said co-author Ruina Zhang, B.S., an NYU medical student. Some limitations of the study are that it relied on questionnaires completed by the participants; it measured how often they ate olive oil, but not how much olive oil they ate; and because it was observational the study could not prove that eating olive oil will reduce platelet activation in obese adults. Co-authors are: Ruina Zhang, A.B.; Manish Parikh, M.D., M.S.; Christine J. Ren-Fielding, M.D.; Sally M. Vanegas, Ph.D.; Melanie R. Jay, M.D., M.S.; Karry Calderon, A.B.; Edward A. Fisher, M.D., Ph.D., M.P.H.; and Jeffrey S. Berger, M.D., M.S. Author disclosures are on the abstract. The National Institutes of Health funded the study. Additional Resources: Multimedia including AHA volunteer expert, Linda Van Horn, PhD, RDN, FAHA, offers perspective (via audio/photo). Download and transcript available on the right side of the release link https://newsroom.heart.org/news/eating-olive-oil-once-a-week-may-be-associated-with-making-blood-less-likely-to-clot-in-obese-people?preview=e28fb9b9b48136de11a0336284e6c5ac Spanish release Managing Your Weight Mediterranean diet with virgin olive oil may be recipe for ‘good’ cholesterol For more news from AHA EPI Lifestyle Conference 2019, follow us on @HeartNewsTwitter #EPILifestyle19. Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device ...
Fountain Valley, CA, March 07, 2019 (NewMediaWire) -- Triad Pro Innovators, Inc. (OTC Pink; TPII): Triad Pro is proud to announce a new breakthrough in its eCell energy storage technology. Triad Pro’s new power supply design, which just passed its final development milestone, can now provide access of up to 90% of the stored energy in its eCell, as opposed to common battery storage systems, which can only access 30-35% of stored energy. The Triad Pro eCell uses static dynamic storage elements, as opposed to the liquids used in a chemical battery. In off-grid scenarios and applications energy storage using traditional battery systems has many shortfalls: 1) they take too long to charge; 2) have limited variability at discharge; 3) require maintenance; 4) need to be replaced often due to limited charge/discharge cycles; 5) suffer from drastically reduced performance in extreme temperatures; 6) are routinely overbuilt to compensate for these weaknesses, or are not used at all. The newly developed Triad Pro power supply provides our storage system with tremendous operational flexibility. Using our propriety hardware and software solution, our eCell can be configured to store energy at a rate limited only by the network providing it, and then release that energy in a regulated way based upon the application, which allows for flexibility unknown in current chemical battery-based storage systems.For additional information about Triad Pro Innovators visit the website at: triadproinc.com Forward-looking Statements: This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as “expect”, “believe” or “plan”, by their nature address matters that are, to different degrees, uncertain. The information in this release is provided only as of the date of this release, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except as required by law.Murray Goldenberg 3108902209 m.gol@verizon.net
Chatsworth, CA - (NewMediaWire) - March 07, 2019 - Cavitation Technologies, Inc. (OTCQB: CVAT) (BERLIN: WTC) is pleased to announce that it received 2 new purchase orders from Desmet Ballestra Group, a strategic partner and licensee of Cavitation Technologies, Inc.’s vegetable oil refining technology since 2010.The Nano Reactor® systems will be installed for use in a vegetable oil refinery in Mexico at both ~200 and 400 metric tonnes per day (MTPD). The Company anticipates receiving $200,000 in the aggregate from this order and expects to record the revenue in the third quarter of Fiscal 2019.Igor Gorodnitsky, President of CTi, said, “We are delighted to receive not one, but two more purchase orders from our strategic partner, Desmet Ballestra. This will be the 16th and 17th installation in North and South America combined and the 3rd and 4th in Mexico.”About CTiFounded in 2007, the company designs and manufactures innovative flow-through devices and systems, as well as develops processing technologies for use in edible oil refining, renewable fuel production, water treatment, and alcoholic beverage enhancement. The company's patented Nano Reactor® systems and various technologies have over 30 patents issued and filed both domestically and abroad. http://www.ctinanotech.com/Follow us on Twitter for real time updates: https://twitter.com/CavitationTech Like us on Facebook to receive live feeds updates: https://www.facebook.com/ctinanotech Check us out on LinkedIn: https://www.linkedin.com/company/cavitation-technologiesAbout Desmet Ballestra GroupThe Desmet Ballestra Group provides engineering and supply of plants and equipment for the following industries worldwide:Oils and Fats and Animal FeedDetergents, Surfactants and related ChemicalsOleochemical and BiodieselDesmet Ballestra's R&D Team is composed of professionals specialized in Oils and Fats, oleochemicals and chemical processes, using the most comprehensive set of technological resources and equipment. Controlled by Financière DSBG, a holding company based in Paris, France, the Desmet Ballestra Group is present in all major market areas of the world through its integrated business units located in Northern and Central America (USA, Mexico), South America (Argentina, Brazil, Colombia), Asia & Far East (PR China, Singapore, Malaysia), India and Europe (Belgium, Turkey, Russia, Spain). http://www.desmetballestra.com/Forward Looking StatementThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on ...
Fort Lauderdale, FL - (NewMediaWire) - March 7, 2019 - MediXall Group Inc., (OTCQB: MDXL), division of MediXall.com, a technology and innovation-driven organization focused on transforming the patient-provider experience, is pleased to announce today the company’s expansion into the eye care arena with the appointment of Dr. Howard J. Braverman to the MediXall Advisory Board.Dr. Braverman’ s distinguished career of more than 40 years in the eye care industry includes practicing optometry in Florida for more than 28 years, as well as serving as the President of the American Optometric Association. Most notably, he was the National Vision Director for Humana’s Employer Group Segment. Dr. Braverman will provide guidance and support on strategic initiatives, as well as homing in on the patient-provider experience, as he has years of industry experience working directly with patients.Patients today expect seamless and personalized experiences when it comes to their healthcare, which is why MediXall developed a new tool for physicians to engage their patients with the level of price transparency and digital convenience that they have come to expect in every other aspect of their lives. With Braverman’s direct patient-provider experience, he will guide MediXall on optimizing the new MediXall Patient Experience, so that it integrates patient relationship management/commerce with digital marketing solutions to help grow their practice, improve office efficiency, and optimize appointment capacity.“Dr. Braverman is well-known and respected throughout the healthcare industry and is an outstanding business person with strategic vision and excellent execution skills,” said Michael Swartz, President of MediXall. “We're fortunate to have Dr. Braverman on our advisory board to assist with the critical areas of identifying and pursuing key strategies to help facilitate MediXall’s roll-out into the Vision space. His impressive 40-year career in optometry, coupled with his experience serving in various leadership capacities within the healthcare industry, will be a valuable resource for our team as we continue to expand our services and streamline efficiency with our platform overall.”Dr. Braverman’s previous experience included serving as President of The Vision Division of CompBenefits, Inc. He was also the Chief Executive Officer of Ultimate Optical, a wholesale prescription optical laboratory that was part of CompBenefits’ family of companies.Dr. Braverman has also served in a leadership capacity as part of various board and professional organizations. Most notably, he was the President of the American Optometric Association from 2000 –2001. He was also President of the Southern Council of Optometrists in 1993 and named “Optometrist of the South” in 1998. In addition, he served as the Chairman of the Florida State Board of Optometry, has been a member of the Florida Optometric Association, and has served as a trustee of Nova Southeastern University. He is currently a member of the Board of Governors of the Health Professions of Nova Southeastern University.“As a leader in the eye care profession, I am looking forward to working with the MediXall Leadership team’s technology-driven innovations in the patient/ provider experience. MediXall’s digital innovations will be an invaluable aid to help optometrists improve their office efficiency, which in turn allows optometrists to improve the quality of care for patients that they serve every single day,” said Dr. Howard Braverman.As a member of the MediXall advisory board, Dr. Braverman will work closely with the MediXall leadership team to consult on business strategy and sales, marketing, and product plans, as well as identify additional market opportunities and new strategic partnerships for the company. Furthermore, he will provide strategic and tactical insights on finding new ways to help address patients’ vision wellness needs, drive more patients to providers, improve provider growth and profitability, and help develop an eye care marketing campaign.For more information, please ...
Anticipated Revenues Growing at a Staggering PaceNewport Beach, CA - (NewMediaWire) - March 07, 2019 - M Line Holdings, Inc. (OTC Pink: MLHC; "M Line" or the “Company”).After distributing our shareholder letter on February 26, 2019, we wanted to continue to provide more details about the progress of the individual subsidiaries. Our first update is about the Caravel Group. They are having a fantastic first quarter of 2019. Negotiations are in the final stages with many large US retail chains to put our VEA™ branded drinks (VEA™ Proactive Hydration and VEA™ caffeinated sparkling water) on their shelves within the retailers shelf reset schedules. Additionally, we continue to be incredibly excited by our newly formulated TORQUE® Sugar Free Energy Drink and consumer chosen new TORQUE® Flavor line extension. All three brands, TORQUE® Energy Drink, TORQUE® Sugar Free and soon to be announced TORQUE® Flavor Line Extension are receiving very positive feedback from distributors and retailers. On the international stage we are also having great success. Caravel is in negotiations with international distribution partners for the VEA™ Brands and the TORQUE® Energy brands. Our distributor in Mexico is increasing their current purchase orders due to the excitement for the Caravel brands from Mexico’s key retailers.Our first orders of Lorenzo Caputo wine will be available for distribution later this month and we expect rapid growth once the wine brand appears on the TLC Channel, hot non-scripted show, Long Island Medium.Tony Anish, CEO of M Line, commented: “The growth in business that we are experiencing is far beyond what we expected for this year. The sales team at Caravel are doing an amazing job with our beverages. Tony continued: “I want to take this opportunity to again thank all our shareholders for believing in us. We recognize that the most important issue for shareholders is increased shareholder value. As management, we knew that it would take significant funds to build our group of companies and now, in an effort to achieve improved shareholder value, we have taken the following very important steps:I will be negotiating with our debt holders to freeze all dilution for an extended period of time. More details will be given next week.We will be announcing full details of the public company acquisition next week and we will consolidate its results with MLHC. This is not a spin-off but part of our growth.We will announce details next week of our plans to issue a dividend of a portion of the public company stock we acquire, subject to regulatory approval.The current and future prospects of MLHC has never looked brighter and because of the hard work of management and the support of our shareholders, we are now in the position to freeze dilutive measures to help increase the price of our shares”About M Line Holdings, Inc.M Line is a Holding Company. It controls subsidiaries involved in the Beverage Branding and Distribution industry that includes our branded drinks. In addition, M Line controls two subsidiaries in Florida in the Food and Beverage distribution business and M Line has now expanded into the Cannabis Industry with the acquisition of our C-Pod manufacturing business. M Line owns three restaurants and an event center in Arizona and land for development. M Line will continue with its business financing activities while looking for other opportunities in the Beverage, Distribution, hospitality and Cannabis industries as well as other prospects that make sense to management.Safe Harbor and Informational StatementThis press release may contain forward-looking information within the meaning of Section 21E of the Security Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statement of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial conditions or results of operations; (iii): the company's ...
DENVER, CO - (NewMediaWire) - March 07, 2019 - Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”, ”the Company”), an international adaptive healthcare solutions company, today announced that it has broken ground on its first Community Clinic and Dispensing Pharmacy for the treatment of diabetes in the Republic of Vanuatu. The Company held a groundbreaking event at 11:00 a.m. on March 5th in Erakor Village, Vanuatu where the Paramount Chief welcomed Phoenix Life officials, such as Global Head of Security and Transport, Former Police Commissioner John Taleo, Head of National Healthcare, Former Director of Port Vila Central Hospital, the Department of Curative & Hospital Services and Vanuatu’s Ministry of Health, Dr. Santus Wari, and Martin Tindall, Phoenix Life CEO and Founder.According to the International Diabetes Federation, 1 in 10 Vanuatu citizens are diagnosed with diabetes every year. This is why Denver-based Phoenix Life chose to tackle diabetes in The Republic of Vanuatu, with a focus on addressing the national diabetes epidemic with Phoenix Metabolic, a plant based pharmaceutical, extracted from the cannabis plant and designed to specifically manage diabetes and its complications. Phoenix Life intends to deliver programs to make diabetes healthcare more accessible and affordable for national healthcare system providers, such as governments in the developing and least developed nations. “We appreciate the work that Phoenix Life Sciences International is doing in the Republic of Vanuatu to create a solution for our diabetes epidemic using botanical medicine. We’re sorry we were unable to attend the groundbreaking at Erakor Village but we are very excited for the commencement of Phoenix Life’s national diabetes screening and management program in the upcoming months,” said Vanuatu Minister of Health Hon. Jack Norris Kalmet.At the event, Dr. Santus Wari gave a speech on the benefits of this clinic and stressed the importance of citizens participating in blood sugar testing to better understand their health. Phoenix Life CEO Martin Tindall explained the company’s plans to open a national network of Phoenix Life Community Clinics and Dispensing Pharmacies over the next year. Further, Tindall explained that Phoenix Life plans to conduct clinical trials in Vanuatu, to be overseen by leading endocrinologists from Australia and the United States. These double blind randomized clinical trials will be used to confirm the efficacy of Phoenix Metabolic as a treatment for diabetes as part of Phoenix Life’s global rollout strategy.Through this Community Clinic and future locations, Phoenix Life plans to increase healthcare infrastructure throughout the nation to promote better health and provide significant improvements in healthcare, initially in the field of diabetes management. Now at locations around the Island Nation and at the event, Phoenix Life offers complimentary blood sugar screenings to test for diabetes and pre-diabetes in the population. Approximately 400 people were screened at the event. Attendees were served a healthy lunch made of traditional Vanuatu cuisine (Island Kai Kai) and taught about ways to improve their health through clean eating habits. “Diabetes is a disease that affects millions across the globe and is near to my heart as my family, like so many others, has been affected by it,” said Martin Tindall, CEO of Phoenix Life Sciences International Limited. “The groundbreaking of our first Community Clinic and Dispensing Pharmacy for the treatment of diabetes is an exciting next step for Phoenix Life as we work diligently to carry out our mission of transforming international healthcare.”The clinic will be the first of a national network of Community Clinics and Dispensing Pharmacies for Phoenix Life and will feature examination rooms, analytical labs, a dispensing pharmacy and other services for the health of the local people. As Phoenix Life continues rolling out its screening program “Sik Suka ? Jekem Ia !”, and a national network of Community Clinics and Dispensing ...
